These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 816686)

  • 21. [Human brucellosis vaccine obtained from the phenol-insoluble fraction of Brucella abortus strain B 19. Production, control, standardization].
    Desmettre P; Joubert L; Valette L; Roux J
    Dev Biol Stand; 1984; 56():579-86. PubMed ID: 6436115
    [No Abstract]   [Full Text] [Related]  

  • 22. Venezuelan field trials of vaccines against brucellosis in swine.
    Lord VR; Cherwonogrodzky JW; Schurig GG; Lord RD; Marcano MJ; Meléndez GE
    Am J Vet Res; 1998 May; 59(5):546-51. PubMed ID: 9582954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serological findings obtained in cattle herds immunised with the Brucella melitensis Rev.1 and the B. abortus B19 vaccine in Mongolia.
    Dénes B
    Acta Vet Hung; 1997; 45(1):33-43. PubMed ID: 9270127
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of laboratory animals in the potency test of Brucella abortus S.19 vaccine. Response of guinea-pigs to graduated doses of vaccine and challenge.
    Thornton DH; Muskett JC
    J Comp Pathol; 1972 Apr; 82(2):201-8. PubMed ID: 4625200
    [No Abstract]   [Full Text] [Related]  

  • 25. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: immunity.
    Alton GG; Jones LM; García-Carrillo C; Trenchi A
    Am J Vet Res; 1972 Sep; 33(9):1747-51. PubMed ID: 4626469
    [No Abstract]   [Full Text] [Related]  

  • 26. Vaccination with Brucella recombinant DnaK and SurA proteins induces protection against Brucella abortus infection in BALB/c mice.
    Delpino MV; Estein SM; Fossati CA; Baldi PC; Cassataro J
    Vaccine; 2007 Sep; 25(37-38):6721-9. PubMed ID: 17686554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
    Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
    Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunisation of laboratory animals and cattle with non-agglutinogenic extracts of Brucella abortus strain 45-20.
    Sterne M; Trim G; Broughton ES
    J Med Microbiol; 1971 May; 4(2):185-94. PubMed ID: 4998854
    [No Abstract]   [Full Text] [Related]  

  • 29. Resistance against a subcutaneous Brucella challenge of mice immunized with living or dead Brucella or by transfer of immune serum.
    Pardon P
    Ann Immunol (Paris); 1977; 128(6):1025-37. PubMed ID: 413471
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunization against Brucella with killed vaccines. II. Immunizing activity of killed Brucella vaccines in guinea pigs.
    Rasooly G; Olitzki AL; Sulitzeanu D
    Isr J Med Sci; 1967; 3(6):814-21. PubMed ID: 4968077
    [No Abstract]   [Full Text] [Related]  

  • 31. Serologic responses, biosafety and clearance of four dosages of Brucella abortus strain RB51 in 6-10 months old water buffalo (Bubalus bubalis).
    Diptee MD; Adesiyun AA; Asgarali Z; Campbell M; Adone R
    Vet Immunol Immunopathol; 2006 Jan; 109(1-2):43-55. PubMed ID: 16112746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenic activity of a cell wall fraction extracted from Brucella abortus in guinea-pigs.
    Bosseray N; Plommet M; Dubray G
    Ann Microbiol (Paris); 1978; 129 B(4):571-9. PubMed ID: 112900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Brucella melitensis Rev. 1 and Brucella abortus 45-20 vaccines in goats: serologic tests.
    Jones LM; García-Carrillo C; Alton GG
    Am J Vet Res; 1973 Feb; 34(2):199-202. PubMed ID: 4631096
    [No Abstract]   [Full Text] [Related]  

  • 34. Immunopotentiation of live brucellosis vaccine by adjuvants.
    Denisov AA; Korobovtseva YS; Karpova OM; Tretyakova AV; Mikhina LV; Ivanov AV; Salmakov KM; Borovick RV
    Vaccine; 2010 Oct; 28 Suppl 5():F17-22. PubMed ID: 20362624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus.
    Araya LN; Elzer PH; Rowe GE; Enright FM; Winter AJ
    J Immunol; 1989 Nov; 143(10):3330-7. PubMed ID: 2509555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunity to Brucella abortus induced in mice by popliteal lymph node restricted strain 19 vaccination.
    Plommet M; Plommet AM
    Ann Rech Vet; 1989; 20(1):73-81. PubMed ID: 2494933
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic properties of soluble antigens or whole cells of Brucella abortus strain 45/20 associated with immunoadjuvants. II. Whole cells.
    Woodard LF; Toone NM; McLaughlin CA
    Can J Comp Med; 1980 Oct; 44(4):456-8. PubMed ID: 6778600
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice.
    Tabatabai LB; Pugh GW; Stevens MG; Phillips M; McDonald TJ
    Am J Vet Res; 1992 Oct; 53(10):1900-7. PubMed ID: 1456539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Preliminary study of the combination of anti-foot-and-mouth disease and anti-brucellosis vaccines].
    Mastan MB; Amighi M; Ardelan A; Bandpay MR; Ebadi A; Farsi J
    Dev Biol Stand; 1976; 35():437-43. PubMed ID: 198311
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice.
    Bosseray N
    Br J Exp Pathol; 1978 Aug; 59(4):354-65. PubMed ID: 101226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.